Mesa Laboratories (NASDAQ:MLAB) Sees Large Volume Increase - What's Next?

Key Points

• Mesa Laboratories shares rose 6.5% to $104.31 as trading volume increased 76% to 255,936 shares.
• Analysts remain cautious: the consensus rating is “Reduce” with an average price target of $94, while the latest quarter missed expectations on both earnings and revenue.
• The company declared a quarterly dividend of $0.16 per share, representing a 0.6% yield, while insiders sold 8,277 shares worth approximately $770,122 during the last quarter.

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) saw an uptick in trading volume on Tuesday . 255,936 shares were traded during mid-day trading, an increase of 76% from the previous session's volume of 145,662 shares.The stock last traded at $104.31 and had previously closed at $101.62.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Mesa Laboratories from a "sell (d+)" rating to a "sell (d)" rating in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average target price of $94.00.

Mesa Laboratories Trading Up 6.5%

The stock has a market capitalization of $605.85 million, a PE ratio of 90.91 and a beta of 0.92. The firm has a 50-day moving average price of $100.25 and a 200-day moving average price of $95.33. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.78 by ($0.25). The company had revenue of $63.72 million for the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter in the previous year, the company posted ($1.31) EPS.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be paid a dividend of $0.16 per share. The ex-dividend date is Monday, August 31st. This represents a $0.64 annualized dividend and a dividend yield of 0.6%. Mesa Laboratories's dividend payout ratio (DPR) is presently 53.33%.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, CFO John Sakys sold 2,827 shares of the firm's stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares of the company's stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of the business's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the sale, the senior vice president owned 6,377 shares in the company, valued at approximately $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,277 shares of company stock worth $770,122 in the last quarter. Insiders own 2.80% of the company's stock.

Institutional Investors Weigh In On Mesa Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its holdings in Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Mesa Laboratories in the fourth quarter worth about $27,000. Kestra Advisory Services LLC bought a new stake in shares of Mesa Laboratories in the fourth quarter valued at approximately $55,000. BNP Paribas Financial Markets raised its position in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 243 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier's stock valued at $79,000 after buying an additional 684 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source